Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2019 ASCO Annual Meeting

Amy J. Davidoff, PhD, on Racial Disparities in Time to Cancer Treatment: The Effect of Medicaid Expansion

Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy

Ian D. Davis, MBBS, PhD, and Christopher Sweeney, MBBS, on Prostate Cancer: ENZAMET Trial on Enzalutamide for Metastatic Hormone-Sensitive Disease

Sara A. Hurvitz, MD, on HR+/HER2− Advanced Breast Cancer: MONALEESA-7 Trial on Endocrine Therapy With or Without Ribociclib

Josep Tabernero, MD, PhD, on Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Pembrolizumab With or Without Chemotherapy vs Chemotherapy

Edward B. Garon, MD, on Advanced Non–Small Cell Lung Cancer: KEYNOTE-001 Trial on Pembrolizumab

Kamal Chamoun, MD, on Multiple Myeloma: Insurance Status and Survival

Richard L. Schilsky, MD, and R. Donald Harvey, PharmD, BCOP, on Advanced Non–Small Cell Lung Cancer: Expanding the Criteria for Clinical Trial Eligibility

William D. Tap, MD, on Soft-Tissue Sarcomas: ANNOUNCE Trial on Doxorubicin and Olaratumab

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

Richard Pazdur, MD, on the Launch of Project Facilitate

Lee S. Schwartzberg, MD, FACP: 2019 Update on the ACCC Immuno-Oncology Institute: Using Immunotherapy in the Community Setting

Kamran A. Ahmed, MD, on Cervical Cancer: Stereotactic Body Radiation Therapy Plus Atezolizumab

Manmeet S. Ahluwalia, MD, on Glioblastoma: Novel Cancer Vaccine With Standard Therapy

Taofeek Kunle Owonikoko, MD, PhD, on Small Cell Lung Cancer: Tremelimumab and Durvalumab With or Without Radiation

Margaret A. Tempero, MD, on Pancreatic Cancer: Adjuvant Nab-paclitaxel and Gemcitabine

Mark J. Levis, MD, PhD, on Acute Myeloid Leukemia: Gilteritinib in FLT3-Mutated Disease

Karim Fizazi, MD, PhD, on the ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

Rowan T. Chlebowski, MD, PhD, on Breast Cancer Incidence and Mortality: Results From the Women’s Health Initiative on the Effects of a Low-Fat Diet

Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin

David J. Kwiatkowski, MD, PhD, on Non–Small Cell Lung Cancer: Neoadjuvant Immunotherapy for Resectable Disease

Daniel P. Petrylak, MD, on Urothelial Cancer: Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Disease

Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy

Neeraj Agarwal, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: KEYNOTE-426 on First-Line Pembrolizumab Plus Axitinib vs Sunitinib

Neeraj Agarwal, MD, and Arnaud Méjean, MD, PhD, on Renal Cancer: Cytoreductive Nephrectomy Followed by Sunitinib in the Metastatic Setting

Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Adding Bevacizumab to Gemcitabine and Cisplatin

Matt D. Galsky, MD, on Urothelial Cancer: Pembrolizumab vs Placebo After First-Line Chemotherapy

Suresh S. Ramalingam, MD, on Non–Small Cell Lung Cancer: Pemetrexed, Bevacizumab, or Both as Maintenance Therapy

Yoland C. Antill, MD, on Endometrial Cancer: PHAEDRA Trial on Durvalumab and Mismatch Repair Status

Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Miriam Knoll, MD, and Zachery Reichert, MD, PhD, on Prostate Cancer: Focal Radiation for Oligometastatic Castration-Resistant Disease

Paul G. Richardson, MD, on Relapsed or Refractory Multiple Myeloma: Adding Isatuximab to Pomalidomide and Low-Dose Dexamethasone

Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations

Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation

Thomas J. George, MD, on Locally Advanced Rectal Cancer: Total Neoadjuvant Therapy

Brian C. Baumann, MD, on Locally Advanced Cancer: Proton vs Photon Therapy

Brian C. Baumann, MD, on Locally Advanced Bladder Cancer: Adjuvant Radiotherapy After Radical Cystectomy

Michael J. Morris, MD, on Metastatic Prostate Cancer: Adding Abiraterone Acetate to Enzalutamide

Ziad Bakouny, MD, and Toni K. Choueiri, MD, on Renal Cell Carcinoma: Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid/Rhabdoid Disease

Kim N. Chi, MD, on Castration-Resistant Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in the Metastatic Setting

Kim N. Chi, MD, on Metastatic Castration-Sensitive Prostate Cancer: First Results From the TITAN Trial

Francesca Gay, MD, on Multiple Myeloma: Carfilzomib/Lenalidomide/Dexamethasone With or Without Transplantation

Michael A. Thompson, MD, PhD, on Smoldering Multiple Myeloma: Reassessing Risk Stratification Models

Gilberto Lopes, MD, MBA, on the RELAY Trial in Metastatic NSCLC: Erlotinib and Ramucirumab in EGFR Mutant–Positive Disease

Richard T. Penson, MD, and Don S. Dizon, MD, on Ovarian Cancer: SOLO3 Trial on Olaparib vs Chemotherapy in Relapsed Disease

Angela Lamarca, MD, PhD, on Biliary Tract Cancers: Active Symptom Control With Oxaliplatin and Fluorouracil

Panagiotis A. Konstantinopoulos, MD, PhD, on Endometrial Cancer: Avelumab in Microsatellite-Stable and -Instable Disease

Sagar Lonial, MD, on Smoldering Multiple Myeloma: Delaying Disease Progression With an Immunomodulatory Agent

Javier Sastre, MD, PhD, on Colorectal Cancer: Bevacizumab and FOLFOXIRI in Metastatic Disease

Ahmad A. Tarhini, MD, PhD, on High-Risk Melanoma: Adjuvant Ipilimumab vs High-Dose Interferon-α2b

Yeon Hee Park, MD, on Metastatic Breast Cancer: Palbociclib, Exemestane, and GnRH Agonist

William G. Wierda, MD, PhD, on Immunotherapy for Relapsed/Refractory CLL/SLL: Results From TRANSCEND CLL 004

Kerry A. Rogers, MD, on Chronic Lymphocytic Leukemia: Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed or Refractory Disease

Jame Abraham, MD, on NALA Trial Findings in HER2-Positive Metastatic Breast Cancer

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

Adam Brufsky, MD, PhD, on HER2-Positive Metastatic Breast Cancer: NALA Trial on Neratinib vs Lapatinib Plus Capecitabine

Matthew A. Powell, MD, and Don S. Dizon, MD, on Uterine or Ovarian Cancer: Paclitaxel Plus Carboplatin vs Ifosfamide in Chemotherapy-Naive Patients

Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin

Sara A. Hurvitz, MD, on HER2-Positive Breast Cancer: KRISTINE Trial on Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy

Christopher Sweeney, MBBS, and Ian D. Davis, MBBS, PhD, on ANZUP: Taking a Multidisciplinary Approach to Prostate, Kidney, Bladder, Testicular, and Penile Cancers

Leonard J. Appleman, MD, PhD, on Metastatic Renal Cell Carcinoma: Pazopanib vs Placebo After Metastasectomy

Matteo Lambertini, MD, PhD, on Safety of Pregnancy After Treatment for BRCA-Mutated Breast Cancer

Joseph A. Sparano, MD, on Early Breast Cancer: Predicting Prognosis and Treatment Benefit in TAILORx

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Clinical Activity and Tolerability of Selective RET Inhibitor

Mansoor Raza Mirza, MD, and Don S. Dizon, MD, on Recurrent Platinum-Sensitive Ovarian Cancer: Niraparib Plus Bevacizumab

Hani M. Babiker, MD, on Tumor Treating Fields: A Different Approach to Therapy

Åsmund A. Fretland, MD, on Colorectal Cancer Liver Metastases: Laparoscopic vs Open Resection

Hope S. Rugo, MD, and Matteo Lambertini, MD, PhD, on the SOPHIA Trial in HER2-Positive Metastatic Breast Cancer: Chemotherapy Plus Margetuximab vs Trastuzumab

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Atezolizumab Plus Nab-paclitaxel

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Breast Cancer: Next Steps in Immunotherapy

François-Xavier Mahon, MD, PhD, on Chronic-Phase Chronic Myeloid Leukemia: Treatment-Free Remission After Second-Line Treatment


NCCN Annual Conference 2019

Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: New Immunotherapy Strategies in the NCCN Guidelines

Eric Jonasch, MD, on Kidney Cancer: A Year in Review

Melinda L. Telli, MD, on NCCN Guidelines Updates for HR-Positive, HER2-Negative Early-Stage Breast Cancer

Neil P. Shah, MD, PhD, on CML: NCCN Guidelines Updates on Discontinuing Tyrosine Kinase Inhibitor Therapy

Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals

Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates

James L. Mohler, MD, on Managing Prostate Cancer: NCCN Guidelines Updates

Michelle B. Riba, MD, on Screening for Distress in Cancer: Implementing the Standard of Care

Wells A. Messersmith, MD, on Managing Metastatic Colorectal Cancer: NCCN Guidelines Update

Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice


2019 Multidisciplinary Thoracic Cancers Symposium

Leora Horn, MD, on Small Cell Lung Cancer and Immuno-oncology: Have We Finally Solved the Small Cell Paradox?

Heather A. Wakelee, MD, on Advanced Non–Small Cell Lung Cancer: State-of-the-Art Treatment for EGFR-Positive and ALK-Positive Diseases

Aaron S. Mansfield, MD, on Treating Rare Thoracic Cancers: Status Update

Shraddha M. Dalwadi, MD, MBA, on Non–Small Cell Lung Cancer: What Contributes to Disparities in Treating Stage I Disease

J. Fletcher Drogos, MD, on Multiple Courses of Stereotactic Body Radiation Therapy: Outcomes in Patients With Lung Cancer

Kyle F. Concannon, MD, on Lung Cancer in Homeless Patients: Outcomes and Quality Measures

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Survival Outcomes and Clinical and Molecular Features

Martin Edelman, MD, on Immunotherapy: How Safe Is It for Patients With Autoimmune Disease?

Jing Zeng, MD, on Non–Small Cell Lung Cancer: Therapeutic Implications of Proper Disease Staging

Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes

Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment

Jyoti D. Patel, MD, on Stage III Non–Small Cell Lung Cancer: A Look at New Systemic Treatments


2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Toni K. Choueiri, MD, and Ziad Bakouny, MD, on Renal Cell Carcinoma: Next-Generation Immuno-oncology Therapies

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Building on Recent Successes

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Predicting Response to PD-1 Inhibitors With cfDNA

Madhav V. Dhodapkar, MBBS, on Cancer Vaccines: Emerging Trends

Kim A. Margolin, MD, on Promising Immunotherapy Strategies

Nicholas Vogelzang, MD, on Urothelial Cancer: Results From a Trial on Lenvatinib Plus Pembrolizumab

G. Travis Clifton, MD, on Breast Cancer and Disease Recurrence: Final Analysis From a Study of Nelipepimut-S, GM-CSF, and Trastuzumab

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Stefan O. Ciurea, MD, on Infusing High Doses of Natural Killer Cells: An Enhanced Antitumor Effect


2019 Genitourinary Cancers Symposium

Brian I. Rini, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Results From the KEYNOTE-426 Trial on Pembrolizumab Plus Axitinib vs Sunitinib

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial on Abiraterone Acetate Plus Prednisone

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Trial Results on Avelumab Plus Axitinib vs Sunitinib

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Brian C. Baumann, MD, on Bladder Cancer: Trial Results on Adjuvant Chemoradiotherapy vs Adjuvant Radiotherapy Alone

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study on Nivolumab

Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the ARAMIS Trial on Darolutamide

Silke Gillessen, MD, on Prostate Cancer: Results From the REDUSE Trial on Denosumab

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Rana R. McKay, MD, on Renal Cell Carcinoma: Results From a Trial on Atezolizumab and Bevacizumab

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Craig R. Nichols, MD, on Testicular Cancer Cases: Should They Be Discussed With High-Volume Centers?

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Sumanta K. Pal, MD, on Clinical Cancer Advances: The 14th Annual Report

Sumit K. Subudhi, MD, PhD, on Prostate Cancer: Results From the CheckMate 650 Trial on Nivolumab and Ipilimumab


2019 Gastrointestinal Cancers Symposium

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

Manish A. Shah, MD, on Gastric Cancer: Results From the GAMMA-1 Study on First-Line Combination Therapy

Ahmed Omar Kaseb, MD, on Liver Cancer: Results From an Immunotherapy Trial

Heinz-Josef Lenz, MD, on BRAF V600E–Mutated Biliary Tract Cancer: Results From the ROAR Basket Trial

Carl C. Schimanski, MD, PhD, on Colorectal Cancer Liver Metastases: Study Results on Tecemotide After Surgery

Heinz-Josef Lenz, MD, on Pancreatic Cancer Tumor Profiling and Treatment Response: Results From the COMPASS Trial

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy

Andrew X. Zhu, MD, PhD, on Liver Cancer: Outcomes in the REFLECT Study on Lenvatinib

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results From the KEYNOTE-158 Trial on PD-1 Inhibition

Takashi Kojima, MD, on Esophageal Cancer: Results From the KEYNOTE-181 Trial on Immunotherapy vs Chemotherapy

Francesca Battaglin, MD, on Colorectal Cancer: Using Genetic Variants to Predict Treatment Efficacy

Pieter Tanis, MD, PhD, on Colon Cancer: Results From the COLOPEC Trial on Adjuvant HIPEC

Andrew X. Zhu, MD, PhD, on Pancreatic Cancer: Results From the Prep-02/JSAP-05 Trial

Rongbo Lin, MD, on Gastric Cancer: Results From the FNF-004 Trial


Patients Speak

Facing Death: Having the Difficult Conversation With Your Patients


2018 San Antonio Breast Cancer Symposium

Sara A. Hurvitz, MD, on HER2-Positive Breast Cancer: Novel Treatments and Markers

Xavier Pivot, MD, PhD, on Early Breast Cancer: Results From the PHARE Trial

Kathryn J. Ruddy, MD, MPH, on Breast Cancer and Quality of Life: Expert Perspective

Shoichiro Ohtani, MD, PhD, on Extending Adjuvant Aromatase Inhibitor Therapy: Phase III Trial Results

Zaida Morante, MD, on Triple-Negative Breast Cancer: Delaying Adjuvant Chemotherapy

Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

Andrew D. Seidman, MD, and Charles E. Geyer, MD, on HER2-Positive Breast Cancer: Results From the KATHERINE Trial

Andrew D. Seidman, MD, and Miguel Martín, MD, PhD, on Triple-Negative Breast Cancer: Results From the CIBOMA/GEICAM Trial

Andrew D. Seidman, MD, and Richard G. Gray, MA, MSc, on Long-Term Aromatase Inhibitor Therapy

François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Using Circulating Tumor Cells to Direct Treatment

Harold J. Burstein, MD, PhD, and Daniel F. Hayes, MD, on Breast Cancer With Positive Lymph Nodes: Treatment Controversy

Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery

Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care

Laura S. Dominici, MD, on Young Women With Breast Cancer: Local Therapy and Quality of Life

Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial

Roberto A. Leon-Ferre, MD, on Decreasing Hot Flashes: Results From an ACCRU Trial

Allison Magnuson, DO, on Older Patients With Breast Cancer: A New Tool to Help Guide Treatment Decisions

Kathy S. Albain, MD, on Breast Cancer, Ethnicity, and Clinical Outcomes: Results From the TAILORx Trial

Reshma Jagsi, MD, DPhil, and Rachel A. Freedman, MD, MPH, on Over- and Undertreatment: Getting It Right

Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018: Expert Perspective

Shom Goel, MD, PhD, on Breast Cancer: Impact of CDK4/6 Inhibitors on Immunity

Monica Morrow, MD, on View From the Trenches: What Will You do on Monday Morning?

Hope S. Rugo, MD, on Immunotherapy for Breast Cancer: Expert Perspective

Shanu Modi, MD, on Low HER2-Expressing Breast Cancer: Updated Trial Findings

Hope S. Rugo, MD, on Metastatic Breast Cancer: Treatment for Pretreated Hormone Receptor–Positive Disease


2018 ASH Annual Meeting & Exposition

Gilles A. Salles, MD, PhD, on DLBCL: Results From the L-Mind Treatment Trial

Jennifer Ann Woyach, MD, on CLL: Results From the Alliance North American Intergroup Study

John P. Leonard, MD, on NHL: Results From the AUGMENT Trial

Mikkael A. Sekeres, MD, on MDS: Results From the Medalist Trial

Norman E. Sharpless, MD: Director of the National Cancer Institute: Articulating a Vision

Andreas Burchert, MD, on AML: Results From the Sormain Trial

Francesca M. Gay, MD, on Multiple Myeloma: Results From the Forte Trial

Julie Vose, MD, MBA, and Merav Bar, MD, on CAR T-Cell Therapy: Late Effects of CD19-Targeted Treatment

Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy

Saar I. Gill, MD, PhD, on CLL: Trial Results on Anti-CD19 CAR T Cells

Anas Younes, MD, on DLBCL: Phase III Trial Results

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib

Steven M. Horwitz, MD, on PTCL: Results From the ECHELON-2 Trial

Paul Richardson, MD, on Multiple Myeloma: Results From the OP-106 Horizon Trial

Alok A. Khorana, MD, on Reducing VTE Associated With Systemic Cancer Therapy: Results From the CASSINI Trial

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Treatment Trial Results

Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group

Laurie H. Sehn, MD, MPH, on DLBCL: Trial Results on the Prognostic Significance of MYC

Alexander B. Pine, MD, PhD, on Practices and Preferences for Anticoagulant Therapy in Treating VTE


2018 Palliative and Supportive Care in Oncology Symposium

Leslie J. Blackhall, MD, on Unregulated Opioid Access: Consequences and Outcomes

Suleika Jaouad on Making the Most of a Life Interrupted: A Young Adult Perspective on Cancer

Mary K. Buss, MD, MPH, and Candice A. Johnstone, MD, MPH, on Financial Toxicity During Treatment and Beyond

Elizabeth Jane Cathcart-Rake, MD, on Immunotherapy-Related Toxicities: More Common Than Originally Reported?

Betty R. Ferrell, PhD, on Quality of Life in the Era of Immunotherapy

Mary E. Johnson on Holding Vigil With Dying Loved Ones

Mihir M. Kamdar, MD, on Managing Cancer-Related Pain With Artificial Intelligence

Katherine C. Lee, MD, on Emergency Surgery and End-of-Life Care

Eric Roeland, MD, on Preventing Chemotherapy-Induced Vomiting

Charles von Gunten, MD, PhD, on Protecting Opioid Access for Patients in Need

Allison S. Betof Warner, MD, PhD, on Managing Immune-Related Adverse Events: Incorporating Guidelines

Nosayaba Osazuwa-Peters, MPH, PhD, on Suicide Among Male Patients With Cancer: Study Findings


2018 ASTRO Annual Meeting

Bhisham Chera, MD, on Oropharyngeal Cancer: Expert Perspective on Surveillance

Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial

Vinai Gondi, MD, on Treating Brain Metastases, Preserving Cognitive Function

Thomas Galloway, MD, on Oropharyngeal Cancer: Improving Outcomes and Reducing Toxicity

David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial

Alan Pollack, MD, on Prostate Cancer: Results From the SPPORT Trial

David Raben, MD, on NSCLC: Results From the PACIFIC Trial

Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy

Daniel E. Spratt, MD, on Prostate Cancer in African American Men: Results of a Meta-analysis

Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines


ESMO 2018 Congress

Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities

Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy

Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy

Matti S. Aapro, MD, on Immunotherapy in Older Patients

Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments

Ezra E.W. Cohen, MD, on Head and Neck Cancer: Using Curative Immunotherapy

Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments

Jeffrey S. Weber, MD, PhD, on Discontinuing Immunotherapy: When Is the Right Time?

Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057

Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches

Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study

Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy

Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Research Highlights

Laurence Albiges, MD, PhD, on RCC: Challenging Established Front-Line Treatment

Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights

Tony Mok, MD, on NSCLC: Targeted Treatment Update

Nicholas D. James, PhD, MBBS, on Prostate Cancer: Updates From the STAMPEDE Trial

Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights

Caroline Robert, MD, PhD, on Immunotherapy Toxicities: Expert Perspective


NCCN Hematologic Congress

Natalie S. Callander, MD, on Newly Diagnosed Multiple Myeloma: Expert Perspective

Reem Karmali, MD, on Lymphomas and CAR T-Cell Therapy

Shaji K. Kumar, MD, on Multiple Myeloma: Treatment Update

Frederick L. Locke, MD, on CAR T-Cell Therapy: Major Milestones

Jerald P. Radich, MD, on Chronic-Phase CML: Optimizing Tyrosine Kinase Inhibitor Therapy


2018 ASCO Quality Care Symposium

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Douglas W. Blayney, MD, on Quality Care: Better, Safer, Cheaper

Fumiko Ladd Chino, MD, on Opioid-Associated Deaths in Patients With Cancer

Aaron Lyss, MBA, on Getting the Highest-Value Quality Intervention

Jay B. Shah, MD, on Reducing Opioid Use After Urologic Oncology Surgery

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Angela M. Stover, PhD, on Patient-Reported Symptoms: Results From the STAR and PRO-TECT Trials

Lauren P. Wallner, PhD, MPH, on Thyroid Cancer: Reducing Overtreatment With Radioactive Iodine

Jeremy Warner, MD, on Patient Navigation: Weathering the Storm of Cancer Care

Lalan S. Wilfong, MD, on Metastatic Solid Tumors: Limiting Low-Value Care

Monika K. Krzyzanowska, MD, MPH, on Quality Improvement: Avoiding the Pitfalls

Advertisement

Advertisement



Aug
24
Today In Oncology
FDA Pipeline: Priority Reviews in Prostate Cancer, Mantle Cell Lymphoma
Genomic Landscape of Merkel Cell Carcinoma
Addition of Pemetrexed/Carboplatin to Gefitinib in Advanced EGFR-Mutant NSCLC
Swallowing-Related Quality of Life After Radiotherapy vs Surgery for Oropharyngeal Squamous Cell Carcinoma
Impact of Genes on Total Number and Type of Nevi
View More 
Advertisement
Most Read Stories
Neoadjuvant Letrozole Plus Taselisib or Placebo in Postmenopausal Women With ER-Positive, HER2-Negative Early Breast Cancer
Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC
Olaparib/Temozolomide Shows Activity in Patients With Relapsed Small Cell Lung Cancer
Management of HER2-Positive Breast Cancer: Business as Usual?
Total Cumulative Chemotherapy Dose and Survival in Breast Cancer
View More 
© 2019 HSP News Service, L.L.C.